Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo
Author:
Publisher
Elsevier BV
Subject
Immunology
Reference81 articles.
1. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer;Jurado;Clin. Transl. Oncol.,2008
2. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review;Rosell;J. Surg. Oncol.,1990
3. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity;Saxton;Blood,1997
4. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer;Curti;J. Clin. Oncol.,1998
5. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration;Bracci;Clin. Cancer Res.,2007
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08
2. Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology;Frontiers in Veterinary Science;2024-06-06
3. The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy;Pharmaceutics;2022-06-10
4. Karanahan: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting;Breast Cancer: Basic and Clinical Research;2022-01
5. Theoretical premises of a “three in one” therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review;Translational Cancer Research;2021-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3